Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Scientific Indexing Services (SIS)
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image

Huanyu Dou

Huanyu Dou

Huanyu Dou
Assistant Professor, Department of Biomedical Sciences
Texas Tech University, Health Sciences Center El Paso, USA

Biography

I was trained in neuroscience, neuroimmunology, immunology and nanomedicine and have combined these disciplines to lay a foundation for experimental studies into neuroimmunopharmacology, nanobiology and targeted brain delivery. The significance of my research lies in macrophage-targeted therapy for anti-viral and anti-cancer treatment. I developed RVG-nanocomplexes, as cell-based targeting for brain tumor targeting delivery to treat glioma. Importantly, tumor-associated macrophages and microglia (TAMs) have an extraordinary ability to home in on diseased brain sites as the targets, which provide an ideal therapeutic strategy by targeted delivery RVG-nanocomplexes to brain tumor. My current research is focused on the brain specific targeted delivery and cell-based therapies for brain tumor. My laboratory is applying basic biological techniques (in vitro, ex vivo, and in vivo) and nanotechnology to study newly emerging principles of cytokine and immune cells manipulating neuropathogenesis and ligand-nanoparticle conjungations for cell delivery platforms, especially for treatment of glioma. The proposed researches use RVG-nanocomplexe for glioma chemotherapy to better understanding on how the physicochemical properties to RVG-nanocomplexes can be optimized to maximize the dual benefits of a delivery vehicle across BBB and a specific glioma targeting tools. At present, I am studying the roles of conjugating RVG to core-shell structure of nanocomplexes for BBB-penetrating and gliomaassociated macrophages/microglia specific targeting will allow new chemotherapeutic strategy to be developed, therefore providing RVG-nanocomplexes brain tumor targeting delivery for anti-glioma chemotherapy. Based on macrophage affinity nanocomplexes as toxic therapeutics vehicle and RVG-AChR specific binding for brain targeting across BBB, optimizing RVG-nanocomplex and utilizing particle size will achieve for the specific brain tumor targeting and elimination neuronal cell uptake. To study and complete the proposed researches will have better view and direction on how to bring our innovative delivery platform and technology to clinic application in order to achieve our long-term goal of effectively treating glioma patients.

Research Interest

Medicine, Neuroanatomy, Neurosciences, Neurovirology, nanomedicine